VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors

NFATc1 Regulates PD-1 Expression upon T Cell Activation

(2014) K. J. Oestreich et al.   JOURNAL OF IMMUNOLOGY

Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors

(2013) J. Duraiswamy et al.   CANCER RESEARCH

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

The degree of BCR and NFAT activation predicts clinical outcomes in chronic lymphocytic leukemia

(2012) C. Le Roy et al.   BLOOD

VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2

(2012) N G Gavalas et al.   BRITISH JOURNAL OF CANCER

VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer

(2012) M. Terme et al.   CANCER RESEARCH

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

(2011) S.-R. Woo et al.   CANCER RESEARCH

VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2

(2011) Apostolos C. Ziogas et al.   INTERNATIONAL JOURNAL OF CANCER

Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients

(2011) Lukas Baitsch et al.   JOURNAL OF CLINICAL INVESTIGATION

Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model

(2011) Mengde Cao et al.   LABORATORY INVESTIGATION

T cell exhaustion

(2011) E John Wherry   NATURE IMMUNOLOGY

Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion

(2011) R. D. Schreiber et al.   SCIENCE

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

(2010) Kaori Sakuishi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

A Decrease of Regulatory T Cells Correlates With Overall Survival After Sunitinib-based Antiangiogenic Therapy in Metastatic Renal Cancer Patients

(2010) Olivier Adotevi et al.   JOURNAL OF IMMUNOTHERAPY

The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies

(2009) J. Ozao-Choy et al.   CANCER RESEARCH

Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients

(2009) J. S. Ko et al.   CLINICAL CANCER RESEARCH

Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT

(2009) Patrice Dubreuil et al.   PLoS One

The VEGF-induced transcriptional response comprises gene clusters at the crossroad of angiogenesis and inflammation

(2009) Bernhard Schweighofer et al.   THROMBOSIS AND HAEMOSTASIS

Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients

(2008) J. H. Finke et al.   CLINICAL CANCER RESEARCH

Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis

(2008) Christian Stockmann et al.   NATURE

Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection

(2008) Shawn D Blackburn et al.   NATURE IMMUNOLOGY